BACKGROUND: HIV infection causes a range of cognitive and behavioral symptoms that become more frequent and severe as the immune system deteriorates and symptomatic illness ensues. OBJECTIVE: To determine the impact of disease progression on cognitive abilities of Nigerian Africans who present in the HIV/AIDS clinic of the University Teaching Hospital, Benin City, Nigeria, using the CD4 levels as the measure of disease progression. METHODS: A total of 288 subjects comprising 96 randomly selected symptomatic AIDS patients, 96 randomly selected asymptomatic HIV-positive patients and 96 HIV-negative controls participated in the study. Enzyme-linked immunosorbent assay (ELISA) method was used to detect HIV infection, and CD4 levels were obtained for all subjects. The Community Screening Interview for Dementia (CSI 'D') was used to assess cognitive performance of subjects. Subjects were matched for age, sex and level of education. RESULTS: Each category of subjects comprised 48 males and 48 females. The mean ages were 32.94 +/- 8.0 years, 31.47 +/- 6.7 years and 33.56 +/- 7.1 years for the controls, asymptomoatic HIV-positive and symptomatic AIDS subjects respectively (p = 0.127). The mean CD4 levels were 684 +/- 44/microL (controls), 284 +/- 62/microL (asymptomatic HIV positive) and 142 +/- 36/microL (symptomatic AIDS). The mean CS1 'D' scores were 66.46 +/- 1.90 (controls), 66.31 +/- 2.14 (asymptomatic HIV positive) and 56.62 +/- 4.23 (symptomatic AIDS). CONCLUSION: Cognitive abilities of HIV/AIDS patients decline as the disease progresses. This is reflected in the cognitive performances of the symptomatic AIDS patients. The lower the CD4 levels, the worse the cognitive deficits. There was, however, no significant difference in the performance of asymptomatic HIV-positive patients and the controls.
BACKGROUND:HIV infection causes a range of cognitive and behavioral symptoms that become more frequent and severe as the immune system deteriorates and symptomatic illness ensues. OBJECTIVE: To determine the impact of disease progression on cognitive abilities of Nigerian Africans who present in the HIV/AIDS clinic of the University Teaching Hospital, Benin City, Nigeria, using the CD4 levels as the measure of disease progression. METHODS: A total of 288 subjects comprising 96 randomly selected symptomatic AIDSpatients, 96 randomly selected asymptomatic HIV-positivepatients and 96 HIV-negative controls participated in the study. Enzyme-linked immunosorbent assay (ELISA) method was used to detect HIV infection, and CD4 levels were obtained for all subjects. The Community Screening Interview for Dementia (CSI 'D') was used to assess cognitive performance of subjects. Subjects were matched for age, sex and level of education. RESULTS: Each category of subjects comprised 48 males and 48 females. The mean ages were 32.94 +/- 8.0 years, 31.47 +/- 6.7 years and 33.56 +/- 7.1 years for the controls, asymptomoatic HIV-positive and symptomatic AIDS subjects respectively (p = 0.127). The mean CD4 levels were 684 +/- 44/microL (controls), 284 +/- 62/microL (asymptomatic HIV positive) and 142 +/- 36/microL (symptomatic AIDS). The mean CS1 'D' scores were 66.46 +/- 1.90 (controls), 66.31 +/- 2.14 (asymptomatic HIV positive) and 56.62 +/- 4.23 (symptomatic AIDS). CONCLUSION: Cognitive abilities of HIV/AIDSpatients decline as the disease progresses. This is reflected in the cognitive performances of the symptomatic AIDSpatients. The lower the CD4 levels, the worse the cognitive deficits. There was, however, no significant difference in the performance of asymptomatic HIV-positivepatients and the controls.
Authors: Clifford A Smith; Wilfred G van Gorp; Elizabeth R Ryan; Stephen J Ferrando; Judith Rabkin Journal: J Acquir Immune Defic Syndr Date: 2003-05-01 Impact factor: 3.731
Authors: Walter Royal; Mariana Cherner; Jean Carr; Abdulrazaq G Habib; Abimbola Akomolafe; Alashl'e Abimiku; Manhattan Charurat; John Farley; Akinwande Oluyemisi; Ibrahim Mamadu; Joyce Johnson; Ronald Ellis; J Allen McCutchan; J Allen McCutchen; Igor Grant; William A Blattner Journal: J Neurovirol Date: 2012-04-18 Impact factor: 2.643
Authors: Walter Royal; Mariana Cherner; Tricia H Burdo; Anya Umlauf; Scott L Letendre; Jibreel Jumare; Alash'le Abimiku; Peter Alabi; Nura Alkali; Sunday Bwala; Kanayo Okwuasaba; Lindsay M Eyzaguirre; Christopher Akolo; Ming Guo; Kenneth C Williams; William A Blattner Journal: PLoS One Date: 2016-02-01 Impact factor: 3.240